Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The glycobiology of prostate cancer: an update.

Oncogene·2026
Same author

Targeted Prostate Health Checks for prostate cancer in men at high risk: a feasibility pilot in primary and secondary care in North East London.

BJGP open·2026
Same author

Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours.

Cancer medicine·2026
Same author

Diagnostic Accuracy of Liquid-Based Biomarkers for Detecting and Risk Stratifying Upper Tract Urothelial Cancers: A Diagnostic Test Systematic Review by the EAU Guidelines UTUC Panel.

European urology oncology·2026
Same author

Cribriform Gleason pattern 4: active surveillance no more?

BJU international·2026
Same author

SET1B Drives Sustained HIF activity and Disease Progression in Clear Cell Renal Cell Carcinoma.

Cancer research·2026
Same journal

Cannabis and Cannabidiol, GLP-1 Receptors, and Autophagy: The Burgeoning Link Between Cognitive Neurodegeneration With Alzheimer's Disease and Metabolic Disorders.

Discovery medicine·2026
Same journal

The Urgent Need to Assess and Prevent the Deposits of Microplastics and Nanoplastics in Our Brain.

Discovery medicine·2025
Same journal

Bridging the Translational Gap: Prioritizing the Spontaneous Canine Osteoarthritis Model for Preclinical Studies.

Discovery medicine·2025
Same journal

Harnessing the Power of Chlorogenic Acid: Inhibiting IL-2-Mediated Treg Upregulation to Combat Post-Traumatic Osteomyelitis.

Discovery medicine·2025
Same journal

The Relationship of <i>MAPK10P</i> Gene Polymorphism With P-Wave Peak Time and P-Wave Dispersion in Elderly Patients With Paroxysmal Atrial Fibrillation.

Discovery medicine·2025
Same journal

Curcumin Attenuates PD-L1-Positive Neutrophil-Induced T-Lymphocyte Apoptosis and Alleviates Lung Injury During Sepsis in Rats.

Discovery medicine·2025
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Targeting alternative splicing in prostate oncology.

Phillippa J Carling1, David J Elliott, Craig N Robson

  • 1Institute of Human Genetics, Newcastle University, Newcastle NE1 7RU, United Kingdom.

Discovery Medicine
|October 1, 2009
PubMed
Summary
This summary is machine-generated.

Prostate cancer

More Related Videos

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

Related Experiment Videos

Last Updated: Jun 20, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

Area of Science:

  • Uro-oncology
  • Molecular Medicine
  • Cancer Genetics

Background:

  • Prostate cancer is a common malignancy in aging males, presenting significant clinical challenges due to its biological heterogeneity.
  • Tumor genetic composition, particularly alternative pre-messenger RNA (pre-mRNA) splicing, significantly contributes to this disease complexity.
  • Alternative splicing affects ~95% of protein-encoding gene transcripts, generating diverse protein isoforms with varied functions.

Purpose of the Study:

  • To investigate the role of aberrant and alternative splicing in prostate cancer's biological heterogeneity.
  • To explore the potential of prostate cancer-specific splice variants as novel biomarkers and therapeutic targets.

Main Methods:

  • Analysis of pre-mRNA splicing patterns in prostate cancer.
  • Identification and characterization of prostate cancer-specific splice variants.

Main Results:

  • Emerging evidence indicates that aberrant and alternative splicing contributes to prostate cancer heterogeneity.
  • Prostate cancer-specific splice variants have been identified.

Conclusions:

  • Aberrant splicing is a key driver of prostate cancer's biological diversity.
  • Identifying specific splice variants offers potential for new diagnostic biomarkers and therapeutic strategies to enhance patient outcomes.